¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, ±Ô¸ð, Á¡À¯À², »ê¾÷ ºÐ¼® º¸°í¼­ : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ¿¹Ãø(2025-2034³â)
Prostate Cancer Biomarker Market Size, Share, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By Application, By End Use, and By Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1762314
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 129 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,900,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,288,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,676,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 155¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ »ó¼¼ÇÑ ÅëÂû·Â°ú ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿´Â Àü¸³¼±¾ÏÀÇ Á¸Àç, º´±â, ÁøÇàÀ» È®ÀÎÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ü¾× ¹× Á¶Á÷ À¯·¡ÀÇ ºÐÀÚ ÁöÇ¥ÀÔ´Ï´Ù. À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇп¡¼­ AI¿Í °°Àº ¸ÖƼ¿À¹Í½º Á¢±Ù¹ýÀÇ ÅëÇÕÀ¸·Î Áø´Ü Á¤È®µµ Çâ»ó°ú Áúº´ °èÃþÈ­°¡ ÁøÇàµÇ¾î ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±¤¹üÀ§ÇÑ ÇÁ·ÎÆÄÀϸµ ±â¼úÀº ´õ ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» °¡Áø »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ¹ß°ßÀ» °¡´ÉÇÏ°Ô Çϰí, º¸´Ù Á¤È®ÇÑ È¯ÀÚ ºÐ·ù¿Í ¸ÂÃãÇü Ä¡·á Àü·«À» Áö¿øÇÕ´Ï´Ù. ¸ÖƼ¿À¹Í½º ±â¹Ý ¹ÙÀÌ¿À¸¶Ä¿ Ç÷§ÆûÀÇ Ã¤ÅÃÀº ¸ÂÃãÇü ¾Ï Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀÓ»ó ¹× ¿¬±¸ ºÐ¾ß¿¡¼­ Á¡Á¡ ´õ Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ºñħ½ÀÀû, Àúħ½ÀÀû Áø´Ü ±â¼úÀÇ ¹ßÀüÀÌ ½ÃÀå °³Ã´À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾×ü »ý°ËÀº Ç÷¾×À̳ª ¼Òº¯ »ùÇÃÀ» ÅëÇØ Àü¸³¼±¾ÏÀ» °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ±âÁ¸ÀÇ Á¶Á÷ »ý°ËÀ» ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù ¾ÈÀüÇÏ°í Æí¸®ÇÑ ¹æ¹ýÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹æ¹ýÀº ȯÀÚÀÇ ¼øÀÀµµ¸¦ Çâ»ó½Ã۰í, ½Ç½Ã°£ Áúº´ ¸ð´ÏÅ͸µ°ú Ä¡·á¹ý Á¶Á¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ Á¶±â ¹ß°ß°ú ´ú ħ½ÀÀûÀÎ Áø´ÜÀ» ¿ì¼±½ÃÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Çõ½Å ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, Àü¸³¼±¾Ï °ü¸®ÀÇ Çõ½Å¿¡ ÀÖ¾î ÷´Ü ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀÇ ¿ªÇÒÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù.

Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼­ - ÁÖ¿ä ³»¿ë

À¯Çüº°·Î´Â ´Ü¹éÁú ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß°¡ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ÀÌ´Â ±¤¹üÀ§ÇÑ ÀÓ»ó Àû¿ë°ú ¿©·¯ ´Ü°èÀÇ Áúº´ °ü¸® ´Ü°è¿¡ °ÉÃÄ È®¸³µÈ °ËÁõÀ» µÞ¹ÞħÇÏ´Â °ÍÀ¸·Î ºÐ¼®µÆ½À´Ï´Ù.

¿ëµµº°·Î´Â °³ÀθÂÃãÇü Ä¡·á Á¢±Ù¹ý°ú Á¤¹ÐÄ¡·áÀÇ µµÀÔÀÌ È®´ëµÊ¿¡ µû¶ó µ¿¹ÝÁø´Ü ºÐ¾ß°¡ °¡Àå ºü¸£°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

2024³â ºÏ¹Ì´Â Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» À¯ÁöÇߴµ¥, ÀÌ´Â Á¤±³ÇÑ ÀÇ·á ½Ã½ºÅÛ, Áúº´¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ¹× ¹ÙÀÌ¿À Á¦¾à ±â¾÷ÀÇ ÁýÀû¿¡ ±âÀÎÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº ÇコÄɾî Áö½ÄÀÇ Çâ»ó, Áø´Ü ´É·Â ½ÃÀå °³Ã´, ½ÅÈï±¹ÀÇ ¾Ï ¹ßº´·ü Áõ°¡¿¡ ÈûÀÔ¾î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ½ÃÀå ¼ºÀåÀ» ´Þ¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÁÖ¿ä ¼¼°è ±â¾÷À¸·Î´Â Arquer Diagnostics, Beckman Coulter, Bio-Techne, DiaCarta, Exact Sciences Corporation, ExoDx, Genomic Health, GenPath, Oncology, MDxHealth, Myriad Genetics, Nucleix, OPKO Health, Proteomedix, Veracyte Oncology, MDxHealth, Myriad Genetics, Nucleix, OPKO Health, Proteomedix, Veracyte µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : À¯Çüº°

Á¦6Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ¿ëµµº°

Á¦7Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

Á¦8Àå ¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The prostate cancer biomarkers market size is expected to reach USD 15.58 billion by 2034, according to a new study by Polaris Market Research. The report "Prostate Cancer Biomarker Market Share, Size, & Industry Analysis Report: By Type (Genetic Biomarkers, Protein Biomarkers, Cell-Based Biomarkers, and Metabolomic Biomarkers), By application, By End Use, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Prostate cancer biomarkers are molecular indicators derived from bodily fluids or tissues that aid in identifying the presence, stage, or progression of prostate cancer. The integration of multi-omics approaches such as AI in genomics, proteomics, and metabolomics to improve diagnostic precision and disease stratification further boosts the market demand. These wide profiling techniques allow the discovery of novel biomarkers with greater sensitivity and specificity, supporting more accurate patient categorization and tailored treatment strategies. The adoption of multi-omics-driven biomarker platforms is becoming increasingly central to clinical and research settings as the focus on individualized cancer care intensifies.

The advancement of noninvasive and minimally invasive diagnostic techniques is boosting the market development. Liquid biopsies are gaining traction for their ability to detect and monitor prostate cancer using blood or urine samples, offering a safer and more convenient alternative to traditional tissue biopsies. These methods improve patient compliance and allow for real-time disease monitoring and therapy adjustment. The demand for such innovations continues to grow as healthcare systems prioritize early detection and less invasive diagnostics, reinforcing the role of advanced biomarker technologies in transforming prostate cancer management.

Prostate Cancer Biomarker Market Report Highlights

In terms of type, the protein biomarkers segment accounted for the largest market share in 2024, supported by their extensive clinical applications and well-established validation across multiple disease management phases.

Based on application, the companion diagnostics segment is anticipated to experience the most rapid expansion, propelled by growing implementation of personalized treatment approaches and precision therapies.

In 2024, North America maintained the largest revenue share of the prostate cancer biomarker market, owing to its sophisticated healthcare systems, elevated disease awareness, and concentration of diagnostic and biopharmaceutical firms.

The Asia Pacific market is projected to achieve the fastest market growth during the forecast period, driven by improving healthcare knowledge, developing diagnostic capabilities, and increasing cancer prevalence in emerging nations.

A few global key market players include Arquer Diagnostics; Beckman Coulter, Inc.; Bio-Techne; DiaCarta; Exact Sciences Corporation; ExoDx; Genomic Health; GenPath Oncology; MDxHealth; Myriad Genetics, Inc.; Nucleix; OPKO Health, Inc.; Proteomedix; and Veracyte, Inc.

Polaris Market Research has segmented the prostate cancer biomarker market report on the basis of type, application, end use, and region:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Genetic Biomarkers

Protein Biomarkers

Cell-based Biomarkers

Metabolomic Biomarkers

By Application Outlook (Revenue, USD Billion, 2020-2034)

Screening and Early Detection

Diagnosis and Risk Stratification

Prognosis and Treatment Monitoring

Companion Diagnostics

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Hospitals & Diagnostic Laboratories

Academic & Research Institutes

Biopharmaceutical Companies

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Prostate Cancer Biomarker Market Insights

5. Global Prostate Cancer Biomarker Market, by Type

6. Global Prostate Cancer Biomarker Market, by Application

7. Global Prostate Cancer Biomarker Market, by End Use

8. Global Prostate Cancer Biomarker Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â